Extensive screening for occult malignancy in unprovoked venous thromboembolism: A meta-analysis
- PMID: 28753478
- DOI: 10.1016/j.thromres.2017.07.019
Extensive screening for occult malignancy in unprovoked venous thromboembolism: A meta-analysis
Abstract
Background: The present meta-analysis aimed to evaluate the efficacy and sensitivity of an extensive screening strategy for occult malignant diseases in patients with unprovoked venous thromboembolism (VTE).
Methods: We conducted a systematic search of PubMed, Cochrane, EMBASE, and relevant article references. Meta-analysis was used to pool weighted relative risks (RR) for the rate of missed diagnosis, all-cause mortality, and cancer-related mortality. Heterogeneity test was performed using the inconsistency index. Furthermore, pooled analysis of the sensitivity and the proportion of false-positive findings of PET/CT were conducted.
Results: A total of 5 controlled studies were included with 1,115 and 1,159 unprovoked VTE patients receiving limited or extensive screening strategy, respectively. The risk of missed diagnosis (RR, 0.51; 95% CI, 0.20-1.28; P=0.15) was not significantly different between the limited and extensive screening group. Moreover, there was no statistically significant difference in all-cause mortality (RR, 0.86; 95% CI, 0.58-1.27; P=0.44) and cancer-related mortality (RR, 0.86; 95% CI, 0.46-1.62; P=0.65) between the two groups. The pooled sensitivity and proportion of false-positive findings of PET/CT as a screening tool for occult malignancy in patients with unprovoked VTE was 95% (95% CI, 38%-100%) and 33% (95% CI, 20%-47%), respectively.
Conclusions: Extensive screening strategy did not show a clinically significant benefit over limited screening strategy. Considering the high cost and the additional physical and emotional harm, current evidence did not support extensive screening for each patient in the setting.
Keywords: Extensive screening strategy; Limited screening strategy; Meta-analysis; Occult malignancy; Venous thromboembolism.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.Lancet Oncol. 2016 Feb;17(2):193-199. doi: 10.1016/S1470-2045(15)00480-5. Epub 2015 Dec 8. Lancet Oncol. 2016. PMID: 26672686 Clinical Trial.
-
Positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study.Medicine (Baltimore). 2014 Nov;93(21):e110. doi: 10.1097/MD.0000000000000110. Medicine (Baltimore). 2014. PMID: 25380083 Free PMC article.
-
Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism.Thromb Res. 2018 Nov;171:92-96. doi: 10.1016/j.thromres.2018.09.055. Epub 2018 Sep 23. Thromb Res. 2018. PMID: 30268858
-
Venous thromboembolism and occult cancer: impact on clinical practice.Thromb Res. 2016 Apr;140 Suppl 1:S8-11. doi: 10.1016/S0049-3848(16)30091-3. Thromb Res. 2016. PMID: 27067984 Review.
-
Screening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions.Eur J Haematol. 2023 Jan;110(1):24-31. doi: 10.1111/ejh.13874. Epub 2022 Oct 17. Eur J Haematol. 2023. PMID: 36192850 Free PMC article. Review.
Cited by
-
Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.Cochrane Database Syst Rev. 2021 Oct 1;10(10):CD010837. doi: 10.1002/14651858.CD010837.pub5. Cochrane Database Syst Rev. 2021. PMID: 34597414 Free PMC article.
-
Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?Cureus. 2020 Feb 10;12(2):e6934. doi: 10.7759/cureus.6934. Cureus. 2020. PMID: 32051805 Free PMC article.
-
Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.Cochrane Database Syst Rev. 2018 Nov 8;11(11):CD010837. doi: 10.1002/14651858.CD010837.pub4. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 Oct 1;10:CD010837. doi: 10.1002/14651858.CD010837.pub5. PMID: 30407621 Free PMC article. Updated.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources